SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Definium Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company was founded by Stephen L. Hurst, Scott M. Freeman, Leonard Latchman and Jamon Alexander Rahn on July 26, 2010 and is headquartered in New York, NY.

Definium Therapeutics Inc.

Definium Therapeutics is drawing heavy investor attention as the market anticipates a catalyst-heavy year, featuring three critical Phase 3 data readouts for its lead psychiatry program. While some community members voice concerns over potential share dilution and historical management turnover, bullish sentiment remains centered on the company's strong cash position and the regulatory potential for its novel LSD-based therapy in a massive total addressable market.

Zillow Group, Inc. engages in the provision of real estate and home-related information marketplaces on mobile and the web. The company was founded by Richard N. Barton and Lloyd D. Frink in December 2004 and is headquartered in Seattle, WA.

Zillow Group Inc - Ordinary Shares - Class C

Zillow Group Inc Class C

Zillow is facing significant downward pressure as investors react to an antitrust lawsuit filed by the FTC and several states over allegations of anti-competitive practices in rental advertising. The community is actively debating the stock's future, with many weighing the impact of legal risks against Zillow's strategic integration of AI and its position as a dominant, profitable leader in the housing market.

The GEO Group, Inc. engages in the design, financing, development, and support services for secure facilities, processing centers, and community re-entry facilities. It operates through the following segments: U.S. Secure, Electronic Monitoring and Supervision, Reentry, and International Services. The U.S. Secure Services segment encompasses the United States-based public-private partnership corrections and detention business. The Electronic Monitoring and Supervision Services segment conducts its services in the U.S. The Reentry Services Segment consists of various community-based and reentry services. The International Services segment consists of public-private partnership secure services operations in Australia and South Africa. The company was founded by George C. Zoley in 1984 and is headquartered in Boca Raton, FL.

Geo Group, Inc.

Geo Group is experiencing significant momentum driven by government-backed ICE funding and the strategic expansion of detention capacity, with the community actively discussing a potential short squeeze fueled by high institutional ownership and speculative long-dated call options. Investors are closely tracking the company's role in federal immigration enforcement and the potential for asset sales or a government-led acquisition to unlock value.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is trending as the market digests strong trading updates and continued progress on strategic nuclear projects like SMRs, even as investors navigate ongoing volatility from geopolitical tensions in the Middle East. The community is focused on the company's resilient profit outlook and major defense-related contract wins, which are being weighed against broader concerns about fuel costs and global travel demand.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku shares are surging following a Bloomberg report that the company is exploring strategic options, including a potential sale to a major media firm. The news has ignited significant community debate, with traders analyzing the stock's newfound momentum, the viability of various buyout candidates, and the potential for a larger breakout as institutional interest grows.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis Corp 

Trulieve Cannabis Corp is currently trending as the first major U.S. cannabis company to uplist to the NYSE, a milestone that has triggered intense discussion regarding institutional liquidity and potential regulatory shifts. The community is actively debating the company's valuation and strategic direction following the recent departure of a top executive, while closely monitoring market volatility related to broader sector index rebalancing.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera Biologics is currently a major focus for traders as they anticipate the upcoming Q1 earnings report and critical interim Phase 1 clinical data for its lead candidate, ABCL635. While the community is actively debating the stock's long-term potential versus its history of underperformance, strong institutional accumulation and notable analyst upgrades are driving significant volume and heightened short-interest volatility.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending as traders speculate on potential ecosystem expansion and increased institutional activity, leading to a surge in trading volume and bullish technical breakouts. The community is actively debating the project's long-term utility in the IoT and AI sectors, with many users focused on the impact of Japanese regulatory developments and increased adoption of the Jasmy Global platform.

Intellia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending following a significant capital raise and the announcement of robust Phase 3 trial results for its hereditary angioedema therapy, triggering intense debate among investors regarding dilution versus long-term growth potential. Community sentiment remains polarized, with many investors focused on the company's strong institutional backing and the transformative potential of its CRISPR platform, while others express frustration over the timing and pricing of the share offering.

Tidal Trust II - YieldMax Ultra Option Income Strategy ETF

YieldMax Ultra Option Income Strategy ETF

ULTY is trending due to investor discourse surrounding the fund's recent 1-for-10 reverse stock split and a strategic shift in holdings toward large-cap blue chips to combat ongoing NAV erosion. The community remains deeply divided, with some investors focusing on high yield and potential recovery, while others criticize the fund's performance and payout volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cibus (CBUS) Q1 2026 Earnings Transcript

Cibus (CBUS) Q1 2026 Earnings Transcript...

Cibus (CBUS) Reports Q1 Loss, Beats Revenue Estimates

Cibus (CBUS) delivered earnings and revenue surprises of +5.71% and +29.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Bioceres Crop (BIOX) Reports Q3 Loss, Misses Revenue Estimates

Bioceres Crop (BIOX) delivered earnings and revenue surprises of -220.00% and -29.91%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Cibus (CBUS) Upgraded to Buy: What Does It Mean for the Stock?

Cibus (CBUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Cibus, Inc. (NASDAQ:CBUS) Sees Large Growth in Short Interest

Cibus, Inc. (NASDAQ:CBUS - Get Free Report) was the target of a large increase in short interest during the month of April. As of April 15th, there was short interest totaling 4,106,540 shares, an...

Cibus (CBUS) to Release Earnings on Thursday

Cibus (NASDAQ:CBUS) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-cibus-inc-stock...

Cibus, Inc. (NASDAQ:CBUS) Short Interest Update

Cibus, Inc. (NASDAQ:CBUS - Get Free Report) was the recipient of a large growth in short interest during the month of March. As of March 31st, there was short interest totaling 3,427,664 shares, a growth of 66.8% from the March 15th total of 2,055,342 shares. Currently, 7.2% of the company's stock...

What is HC Wainwright's Forecast for Cibus FY2029 Earnings?

Cibus, Inc. (NASDAQ:CBUS - Free Report) - Analysts at HC Wainwright increased their FY2029 earnings estimates for shares of Cibus in a research report issued on Friday, March 27th. HC Wainwright...

Cibus (NASDAQ:CBUS) Price Target Raised to $3.00 at Jefferies Financial Group

Jefferies Financial Group lifted their price objective on Cibus from $1.90 to $3.00 and gave the company a "hold" rating in a research note on Wednesday...

Sidoti Brokers Increase Earnings Estimates for Cibus

Cibus, Inc. (NASDAQ:CBUS - Free Report) - Equities research analysts at Sidoti upped their Q1 2026 earnings estimates for shares of Cibus in a research note issued to investors on Thursday, March 19th. Sidoti analyst A. Hantman now forecasts that the company will earn ($0.32) per share for the quart...

Cibus, Inc. engages in the research and development of plant traits to seed companies for royalties. It focuses on using gene editing to develop productivity traits in major agricultural crops such as canola, rice, soybean, corn and wheat. The company was founded by Rory Balfour Riggs, Peter Beetham and Greg Gocal in 2001 and is headquartered in San Diego, CA.

CBUSCibus Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CBUS News